Quantcast

KC Reporter

Tuesday, September 9, 2025

Children’s Mercy develops mini-heart organoids for personalized drug screening

Webp o55rv5x2lr56mqa68dv5bdf2ieve

Paul D. Kempinski President and Chief Executive Officer | Children's Mercy Hospital K.C.

Paul D. Kempinski President and Chief Executive Officer | Children's Mercy Hospital K.C.

At Children’s Mercy Hospital in Kansas City, scientists have developed miniature lab-grown hearts known as organoids. These organoids are created from a patient’s own stem cells and are used by doctors to test which medicines might be most effective for individual patients. This approach may help reduce the time spent on finding the right treatment and could decrease reliance on animal testing.

Organoids like these represent a shift in how drugs are tested. The use of animals for drug safety has been required since 1937, after a medication incident resulted in over 100 deaths due to toxicity that was not detected before release. Despite decades of animal testing, some drugs still reach the market with unforeseen toxic effects.

The move toward organoid-based testing is supported by policymakers, researchers, and business leaders who seek more accurate and humane methods for drug development. This change could improve patient safety and lower the costs associated with bringing new drugs to market.

“Children’s Mercy Announces Breakthrough in Personalized Therapy for Rare Genetic Diseases,” said Children's Mercy Research Institute.

For more details, readers can access the full article at Forbes.

ORGANIZATIONS IN THIS STORY

!RECEIVE ALERTS

The next time we write about any of these orgs, we’ll email you a link to the story. You may edit your settings or unsubscribe at any time.
Sign-up

DONATE

Help support the Metric Media Foundation's mission to restore community based news.
Donate

MORE NEWS